观点:细胞治疗、SARS-CoV-2、COVID-19和詹姆斯·林德

Robert P. Gale
{"title":"观点:细胞治疗、SARS-CoV-2、COVID-19和詹姆斯·林德","authors":"Robert P. Gale","doi":"10.1002/acg2.88","DOIUrl":null,"url":null,"abstract":"<p>The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic and resultant coronavirus infectious disease-2019 (COVID-19) create challenges and opportunities for physicians specializing in cell therapy and hematopoietic cell transplants. Recipients of these therapies are at high-infection risk because immune suppression and bone marrow failure from these therapies and their consequences such as cytokine release syndrome (CRS) and chronic graft-<i>versus</i>-host disease (G<i>v</i>HD) and from their underlying disease.</p><p>Little is known about the impact of the SARS-CoV-2 pandemic on cell therapies such as chimeric antigen receptor (CAR)-T-cell therapy. Because CAR-T-cell therapy uses autologous T cells there is no risk of SARS-CoV-2-infection from a donor. However, the recipient may be infected before, during, or after the therapy and unlikely to fare well if given immune suppressive drugs such as cyclophosphamide and fludarabine preinfusion. There may also transportation restrictions if the processing center is remote from the recipient, risk of infection from healthcare provider, family members, etc. Also, because CAR-T-cell recipients are at high risk of CRS, a complication shared with severe COVID-19 and the combination could be fatal. Although there are reasonably convincing data of safety and efficacy on interleukin-6 antagonists in CRS related to CAR-T-cell therapy, most data suggest that this approach is ineffective in COVID-19-related pneumonia.<span><sup>1, 2</sup></span> The US Food and Drug Administration (FDA) has approved a phase-3 placebo-controlled trial of tocilizumab in COVID-19 pneumonia (https://clinicaltrials.gov/ct2/show/NCT04320615); I await results. Elsewhere, my colleagues and I review the possible role of mesenchymal stromal cells in COVID-19-related acute respiratory distress syndrome.<span><sup>3</sup></span> Others are studying placenta or umbilical cord-derived natural killer (NK)-cells (https://www.europeanpharmaceuticalreview.com/news/116794/us-researchers-to-study-stem-cell-therapy-in-covid-19-patients/). Preliminary results of phase-2 trails are being reported, but data are mostly uninterpretable regarding efficacy with appropriate controls. If cell-therapy-based approaches prove safe and effective, operationalizing this will involve hematologists, especially those in cell therapy and/or hematopoietic cell transplantation.</p><p>There are few data about SARS-CoV-2-infection and COVID-19 in persons with hematological cancers. My Chinese colleagues and I studied several aspects of this in Wuhan, epi-center of the SARS-CoV-2 pandemic and in Hubei province. In one study in &gt; 500 persons with chronic myeloid leukemia (CML), we found only five cases of COVID-19.<span><sup>4</sup></span> Although this case rate was substantially higher than the case rate in normals in Hubei province, it is obviously not a serious issue in persons with CML. Risk factors included exposure to someone infected with SARS-CoV-2, no complete hematological remission (CHR), initial presentation as advanced leukemia despite responding to therapy and, possibly, receiving a third-generation tyrosine kinase inhibitor (TKI).</p><p>In another study we compared &gt; 100 hospitalized persons with hematological disorders in two hospitals in Wuhan to similar numbers of healthcare providers in the same hospitals. We found similar COVID-19 case rates, about 10%, but a much higher case fatality rate in the hospitalized hematology patients, about &gt; 60%. We were unable to identify prognostic or predictive covariates in the hematology patients for developing or dying from COVID-19 suggesting the need for careful infection surveillance and possible protective isolation.<span><sup>5</sup></span></p><p>In the third study, we sought to determine safety and efficacy of corticosteroids in persons with COVID-19 and other severe coronavirus infections including SARS-CoV and MERS-CoV in a meta-analysis of 11 studies in 5247 subjects.<span><sup>6</sup></span> Corticosteroid use was associated with delayed virus clearing with no significant reduction in the risk of death. Hospitalization duration was prolonged and the use of mechanical ventilation increased. These data caution against using corticosteroids in persons with severe COVID-19. The three studies I cite are published or in press in <i>LEUKEMIA</i> and available with open access at the NATURE <i>LEUKEMIA</i> website (https://www.nature.com/leu/).</p><p>We also used data from our experience at a transplant center in Hangzhou to suggest guidelines for transplant activities during the SARS-CoV-2 pandemic.<span><sup>7</sup></span> These guidelines are mostly similar to those proposed by others such as the European Bone Marrow Transplant Group (EBMT; https://www.ebmt.org/ebmt/news/coronavirus-disease-covid-19-ebmt-recommendations-update-march-23-2020) and American Society for Transplantation and Cellular Therapy (ASTCT; https://www.journalofclinicalpathways.com/news/astct-releases-interim-guideline-transplantation-during-covid-19), but are based on our <i>real-time</i> experience. None of these so-called guidelines are evidence-based and should be used with this caveat in mind. Guidelines for infection control are available from the European Hematology Association (EHA) and also available at https://www.nature.com/leu/.</p><p>Finally, the rush to try new therapies in persons with SARS-CoV-2-infection and COVID-19 under the banner <i>there is nothing to lose</i> is, I believe, a mistake. Trying new therapies without the evidence of safety and efficacy can cost rather than save lives. With the SARS-CoV-2 pandemic and COVID-19 we have a sudden disruption of 267 years of progress in the evolution of evidence-based medicine. In Royal Navy, surgeon James Lind may have reasoned <i>there is nothing to lose</i> giving two sailors with scurvy two lemons and an orange, but he also gave others cider (not so bad), diluted sulfuric acid (not so good), vinegar, sea water, or a spicy paste as a purgative. Although we lack evidence he had Ethics Committee approval, the pair receiving the lemons and orange improved. We are not told what happened to the others. His discovery resulted in England's mastery over the seas proving it is sometimes better to be lucky than smart. When Captain Cook went on his 1st voyage on the Endeavour to Tahiti in 1768 he carried whiskey mash (not bad), sauerkraut, and a syrup of oranges and lemons.</p><p>However, two lemons and an orange are a far cry from suggesting people take chloroquine, hydroxychloroquine, azithromycin, household disinfectant (I prefer 409), and internal UV-light to prevent or treat SARS-Cov-2-infection or COVID-19. Based on the advertisements in airplane shopping magazines read awaiting takeoff and unable to use your laptop (remember those days) an interval UV light is more likely to grow hair in your oropharynx than cure SARS-CoV-2-infection. We should not let evidence-based medicine be hijacked by politicians, charlatans, and the like. Fortunately, most hematologists are sensible and disciplined; certainly readers of <i>Advances in Cell and Gene Therapy</i> are. Hopefully, we will get through this pandemic with our scientific principles intact.</p><p>None.</p><p>I confirm adhering to the ethical policies of the journal noted on the journal author guidelines page. No ethical approval was required for this Perspective article with no original research data. However, I advise against drinking diluted sulfuric acid.</p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":"3 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.88","citationCount":"1","resultStr":"{\"title\":\"Perspective: Cell therapy, SARS-CoV-2, COVID-19, and James Lind\",\"authors\":\"Robert P. Gale\",\"doi\":\"10.1002/acg2.88\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic and resultant coronavirus infectious disease-2019 (COVID-19) create challenges and opportunities for physicians specializing in cell therapy and hematopoietic cell transplants. Recipients of these therapies are at high-infection risk because immune suppression and bone marrow failure from these therapies and their consequences such as cytokine release syndrome (CRS) and chronic graft-<i>versus</i>-host disease (G<i>v</i>HD) and from their underlying disease.</p><p>Little is known about the impact of the SARS-CoV-2 pandemic on cell therapies such as chimeric antigen receptor (CAR)-T-cell therapy. Because CAR-T-cell therapy uses autologous T cells there is no risk of SARS-CoV-2-infection from a donor. However, the recipient may be infected before, during, or after the therapy and unlikely to fare well if given immune suppressive drugs such as cyclophosphamide and fludarabine preinfusion. There may also transportation restrictions if the processing center is remote from the recipient, risk of infection from healthcare provider, family members, etc. Also, because CAR-T-cell recipients are at high risk of CRS, a complication shared with severe COVID-19 and the combination could be fatal. Although there are reasonably convincing data of safety and efficacy on interleukin-6 antagonists in CRS related to CAR-T-cell therapy, most data suggest that this approach is ineffective in COVID-19-related pneumonia.<span><sup>1, 2</sup></span> The US Food and Drug Administration (FDA) has approved a phase-3 placebo-controlled trial of tocilizumab in COVID-19 pneumonia (https://clinicaltrials.gov/ct2/show/NCT04320615); I await results. Elsewhere, my colleagues and I review the possible role of mesenchymal stromal cells in COVID-19-related acute respiratory distress syndrome.<span><sup>3</sup></span> Others are studying placenta or umbilical cord-derived natural killer (NK)-cells (https://www.europeanpharmaceuticalreview.com/news/116794/us-researchers-to-study-stem-cell-therapy-in-covid-19-patients/). Preliminary results of phase-2 trails are being reported, but data are mostly uninterpretable regarding efficacy with appropriate controls. If cell-therapy-based approaches prove safe and effective, operationalizing this will involve hematologists, especially those in cell therapy and/or hematopoietic cell transplantation.</p><p>There are few data about SARS-CoV-2-infection and COVID-19 in persons with hematological cancers. My Chinese colleagues and I studied several aspects of this in Wuhan, epi-center of the SARS-CoV-2 pandemic and in Hubei province. In one study in &gt; 500 persons with chronic myeloid leukemia (CML), we found only five cases of COVID-19.<span><sup>4</sup></span> Although this case rate was substantially higher than the case rate in normals in Hubei province, it is obviously not a serious issue in persons with CML. Risk factors included exposure to someone infected with SARS-CoV-2, no complete hematological remission (CHR), initial presentation as advanced leukemia despite responding to therapy and, possibly, receiving a third-generation tyrosine kinase inhibitor (TKI).</p><p>In another study we compared &gt; 100 hospitalized persons with hematological disorders in two hospitals in Wuhan to similar numbers of healthcare providers in the same hospitals. We found similar COVID-19 case rates, about 10%, but a much higher case fatality rate in the hospitalized hematology patients, about &gt; 60%. We were unable to identify prognostic or predictive covariates in the hematology patients for developing or dying from COVID-19 suggesting the need for careful infection surveillance and possible protective isolation.<span><sup>5</sup></span></p><p>In the third study, we sought to determine safety and efficacy of corticosteroids in persons with COVID-19 and other severe coronavirus infections including SARS-CoV and MERS-CoV in a meta-analysis of 11 studies in 5247 subjects.<span><sup>6</sup></span> Corticosteroid use was associated with delayed virus clearing with no significant reduction in the risk of death. Hospitalization duration was prolonged and the use of mechanical ventilation increased. These data caution against using corticosteroids in persons with severe COVID-19. The three studies I cite are published or in press in <i>LEUKEMIA</i> and available with open access at the NATURE <i>LEUKEMIA</i> website (https://www.nature.com/leu/).</p><p>We also used data from our experience at a transplant center in Hangzhou to suggest guidelines for transplant activities during the SARS-CoV-2 pandemic.<span><sup>7</sup></span> These guidelines are mostly similar to those proposed by others such as the European Bone Marrow Transplant Group (EBMT; https://www.ebmt.org/ebmt/news/coronavirus-disease-covid-19-ebmt-recommendations-update-march-23-2020) and American Society for Transplantation and Cellular Therapy (ASTCT; https://www.journalofclinicalpathways.com/news/astct-releases-interim-guideline-transplantation-during-covid-19), but are based on our <i>real-time</i> experience. None of these so-called guidelines are evidence-based and should be used with this caveat in mind. Guidelines for infection control are available from the European Hematology Association (EHA) and also available at https://www.nature.com/leu/.</p><p>Finally, the rush to try new therapies in persons with SARS-CoV-2-infection and COVID-19 under the banner <i>there is nothing to lose</i> is, I believe, a mistake. Trying new therapies without the evidence of safety and efficacy can cost rather than save lives. With the SARS-CoV-2 pandemic and COVID-19 we have a sudden disruption of 267 years of progress in the evolution of evidence-based medicine. In Royal Navy, surgeon James Lind may have reasoned <i>there is nothing to lose</i> giving two sailors with scurvy two lemons and an orange, but he also gave others cider (not so bad), diluted sulfuric acid (not so good), vinegar, sea water, or a spicy paste as a purgative. Although we lack evidence he had Ethics Committee approval, the pair receiving the lemons and orange improved. We are not told what happened to the others. His discovery resulted in England's mastery over the seas proving it is sometimes better to be lucky than smart. When Captain Cook went on his 1st voyage on the Endeavour to Tahiti in 1768 he carried whiskey mash (not bad), sauerkraut, and a syrup of oranges and lemons.</p><p>However, two lemons and an orange are a far cry from suggesting people take chloroquine, hydroxychloroquine, azithromycin, household disinfectant (I prefer 409), and internal UV-light to prevent or treat SARS-Cov-2-infection or COVID-19. Based on the advertisements in airplane shopping magazines read awaiting takeoff and unable to use your laptop (remember those days) an interval UV light is more likely to grow hair in your oropharynx than cure SARS-CoV-2-infection. We should not let evidence-based medicine be hijacked by politicians, charlatans, and the like. Fortunately, most hematologists are sensible and disciplined; certainly readers of <i>Advances in Cell and Gene Therapy</i> are. Hopefully, we will get through this pandemic with our scientific principles intact.</p><p>None.</p><p>I confirm adhering to the ethical policies of the journal noted on the journal author guidelines page. No ethical approval was required for this Perspective article with no original research data. However, I advise against drinking diluted sulfuric acid.</p>\",\"PeriodicalId\":72084,\"journal\":{\"name\":\"Advances in cell and gene therapy\",\"volume\":\"3 4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-05-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/acg2.88\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in cell and gene therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/acg2.88\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in cell and gene therapy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acg2.88","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

严重急性呼吸系统综合征-冠状病毒-2 (SARS-CoV-2)大流行及其引发的冠状病毒传染病-2019 (COVID-19)为专门从事细胞治疗和造血细胞移植的医生带来了挑战和机遇。这些疗法的接受者有很高的感染风险,因为这些疗法的免疫抑制和骨髓衰竭及其后果,如细胞因子释放综合征(CRS)和慢性移植物抗宿主病(GvHD),以及它们的潜在疾病。关于SARS-CoV-2大流行对细胞疗法(如嵌合抗原受体(CAR)- t细胞疗法)的影响,人们知之甚少。由于car -T细胞疗法使用的是自体T细胞,因此没有从供体感染sars - cov -2的风险。然而,受体可能在治疗前、治疗中或治疗后感染,如果预先输注环磷酰胺和氟达拉滨等免疫抑制药物,不太可能好转。如果处理中心距离接受者较远,可能存在来自医疗保健提供者、家庭成员等的感染风险,也可能存在交通限制。此外,由于car - t细胞受体患CRS的风险很高,与严重的COVID-19共有的并发症可能是致命的。尽管有相当令人信服的数据表明白细胞介素-6拮抗剂在car - t细胞治疗相关CRS中的安全性和有效性,但大多数数据表明该方法对covid -19相关性肺炎无效。1,2美国食品和药物管理局(FDA)已批准tocilizumab治疗COVID-19肺炎的3期安慰剂对照试验(https://clinicaltrials.gov/ct2/show/NCT04320615);我在等待结果。在其他地方,我和同事们回顾了间充质基质细胞在covid -19相关急性呼吸窘迫综合征中的可能作用其他人正在研究胎盘或脐带衍生的自然杀伤细胞(NK) (https://www.europeanpharmaceuticalreview.com/news/116794/us-researchers-to-study-stem-cell-therapy-in-covid-19-patients/)。正在报告2期试验的初步结果,但在适当控制下的疗效方面,数据大多无法解释。如果以细胞治疗为基础的方法被证明是安全有效的,将涉及血液学家,特别是细胞治疗和/或造血细胞移植的血液学家。关于血液癌患者中sars - cov -2感染和COVID-19的数据很少。我和我的中国同事在武汉(SARS-CoV-2大流行的防疫中心)和湖北省研究了这方面的几个方面。在一项研究&gt;在500例慢性髓性白血病(CML)患者中,我们只发现了5例COVID-19.4,尽管这一发病率大大高于湖北省的正常人,但在慢性髓性白血病患者中,这显然不是一个严重的问题。危险因素包括接触SARS-CoV-2感染者,血液学未完全缓解(CHR),尽管治疗有反应,但最初表现为晚期白血病,并可能接受第三代酪氨酸激酶抑制剂(TKI)。在另一项研究中,我们比较了&gt;武汉两家医院的100名血液病住院患者与同一家医院的相同数量的医疗服务提供者。我们发现相似的COVID-19病例率,约为10%,但住院血液病患者的病死率要高得多,约为10%;60%。我们无法确定血液学患者发生或死于COVID-19的预后或预测性协变量,这表明需要仔细的感染监测和可能的保护性隔离。在第三项研究中,我们通过对11项研究5247名受试者的荟萃分析,试图确定皮质类固醇对COVID-19和其他严重冠状病毒感染(包括SARS-CoV和MERS-CoV)患者的安全性和有效性皮质类固醇的使用与病毒清除延迟有关,但死亡风险没有显著降低。住院时间延长,机械通气使用增加。这些数据告诫严重COVID-19患者不要使用皮质类固醇。我引用的三项研究发表在《白血病》杂志上,并在《自然白血病》网站(https://www.nature.com/leu/).We)上开放获取,也使用了我们在杭州一家移植中心的经验数据,为SARS-CoV-2大流行期间的移植活动提出了指导方针这些指南与欧洲骨髓移植组织(EBMT;https://www.ebmt.org/ebmt/news/coronavirus-disease-covid-19-ebmt-recommendations-update-march-23-2020)和美国移植和细胞治疗学会(ASTCT;https://www.journalofclinicalpathways.com/news/astct-releases-interim-guideline-transplantation-during-covid-19),而是基于我们的实时体验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Perspective: Cell therapy, SARS-CoV-2, COVID-19, and James Lind

The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic and resultant coronavirus infectious disease-2019 (COVID-19) create challenges and opportunities for physicians specializing in cell therapy and hematopoietic cell transplants. Recipients of these therapies are at high-infection risk because immune suppression and bone marrow failure from these therapies and their consequences such as cytokine release syndrome (CRS) and chronic graft-versus-host disease (GvHD) and from their underlying disease.

Little is known about the impact of the SARS-CoV-2 pandemic on cell therapies such as chimeric antigen receptor (CAR)-T-cell therapy. Because CAR-T-cell therapy uses autologous T cells there is no risk of SARS-CoV-2-infection from a donor. However, the recipient may be infected before, during, or after the therapy and unlikely to fare well if given immune suppressive drugs such as cyclophosphamide and fludarabine preinfusion. There may also transportation restrictions if the processing center is remote from the recipient, risk of infection from healthcare provider, family members, etc. Also, because CAR-T-cell recipients are at high risk of CRS, a complication shared with severe COVID-19 and the combination could be fatal. Although there are reasonably convincing data of safety and efficacy on interleukin-6 antagonists in CRS related to CAR-T-cell therapy, most data suggest that this approach is ineffective in COVID-19-related pneumonia.1, 2 The US Food and Drug Administration (FDA) has approved a phase-3 placebo-controlled trial of tocilizumab in COVID-19 pneumonia (https://clinicaltrials.gov/ct2/show/NCT04320615); I await results. Elsewhere, my colleagues and I review the possible role of mesenchymal stromal cells in COVID-19-related acute respiratory distress syndrome.3 Others are studying placenta or umbilical cord-derived natural killer (NK)-cells (https://www.europeanpharmaceuticalreview.com/news/116794/us-researchers-to-study-stem-cell-therapy-in-covid-19-patients/). Preliminary results of phase-2 trails are being reported, but data are mostly uninterpretable regarding efficacy with appropriate controls. If cell-therapy-based approaches prove safe and effective, operationalizing this will involve hematologists, especially those in cell therapy and/or hematopoietic cell transplantation.

There are few data about SARS-CoV-2-infection and COVID-19 in persons with hematological cancers. My Chinese colleagues and I studied several aspects of this in Wuhan, epi-center of the SARS-CoV-2 pandemic and in Hubei province. In one study in > 500 persons with chronic myeloid leukemia (CML), we found only five cases of COVID-19.4 Although this case rate was substantially higher than the case rate in normals in Hubei province, it is obviously not a serious issue in persons with CML. Risk factors included exposure to someone infected with SARS-CoV-2, no complete hematological remission (CHR), initial presentation as advanced leukemia despite responding to therapy and, possibly, receiving a third-generation tyrosine kinase inhibitor (TKI).

In another study we compared > 100 hospitalized persons with hematological disorders in two hospitals in Wuhan to similar numbers of healthcare providers in the same hospitals. We found similar COVID-19 case rates, about 10%, but a much higher case fatality rate in the hospitalized hematology patients, about > 60%. We were unable to identify prognostic or predictive covariates in the hematology patients for developing or dying from COVID-19 suggesting the need for careful infection surveillance and possible protective isolation.5

In the third study, we sought to determine safety and efficacy of corticosteroids in persons with COVID-19 and other severe coronavirus infections including SARS-CoV and MERS-CoV in a meta-analysis of 11 studies in 5247 subjects.6 Corticosteroid use was associated with delayed virus clearing with no significant reduction in the risk of death. Hospitalization duration was prolonged and the use of mechanical ventilation increased. These data caution against using corticosteroids in persons with severe COVID-19. The three studies I cite are published or in press in LEUKEMIA and available with open access at the NATURE LEUKEMIA website (https://www.nature.com/leu/).

We also used data from our experience at a transplant center in Hangzhou to suggest guidelines for transplant activities during the SARS-CoV-2 pandemic.7 These guidelines are mostly similar to those proposed by others such as the European Bone Marrow Transplant Group (EBMT; https://www.ebmt.org/ebmt/news/coronavirus-disease-covid-19-ebmt-recommendations-update-march-23-2020) and American Society for Transplantation and Cellular Therapy (ASTCT; https://www.journalofclinicalpathways.com/news/astct-releases-interim-guideline-transplantation-during-covid-19), but are based on our real-time experience. None of these so-called guidelines are evidence-based and should be used with this caveat in mind. Guidelines for infection control are available from the European Hematology Association (EHA) and also available at https://www.nature.com/leu/.

Finally, the rush to try new therapies in persons with SARS-CoV-2-infection and COVID-19 under the banner there is nothing to lose is, I believe, a mistake. Trying new therapies without the evidence of safety and efficacy can cost rather than save lives. With the SARS-CoV-2 pandemic and COVID-19 we have a sudden disruption of 267 years of progress in the evolution of evidence-based medicine. In Royal Navy, surgeon James Lind may have reasoned there is nothing to lose giving two sailors with scurvy two lemons and an orange, but he also gave others cider (not so bad), diluted sulfuric acid (not so good), vinegar, sea water, or a spicy paste as a purgative. Although we lack evidence he had Ethics Committee approval, the pair receiving the lemons and orange improved. We are not told what happened to the others. His discovery resulted in England's mastery over the seas proving it is sometimes better to be lucky than smart. When Captain Cook went on his 1st voyage on the Endeavour to Tahiti in 1768 he carried whiskey mash (not bad), sauerkraut, and a syrup of oranges and lemons.

However, two lemons and an orange are a far cry from suggesting people take chloroquine, hydroxychloroquine, azithromycin, household disinfectant (I prefer 409), and internal UV-light to prevent or treat SARS-Cov-2-infection or COVID-19. Based on the advertisements in airplane shopping magazines read awaiting takeoff and unable to use your laptop (remember those days) an interval UV light is more likely to grow hair in your oropharynx than cure SARS-CoV-2-infection. We should not let evidence-based medicine be hijacked by politicians, charlatans, and the like. Fortunately, most hematologists are sensible and disciplined; certainly readers of Advances in Cell and Gene Therapy are. Hopefully, we will get through this pandemic with our scientific principles intact.

None.

I confirm adhering to the ethical policies of the journal noted on the journal author guidelines page. No ethical approval was required for this Perspective article with no original research data. However, I advise against drinking diluted sulfuric acid.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信